These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 22475282)
1. Immunotherapy highlights from the 2011 meeting of the American Society of Hematology. Hanley PJ; Bollard CM Expert Rev Hematol; 2012 Apr; 5(2):145-7. PubMed ID: 22475282 [TBL] [Abstract][Full Text] [Related]
2. Highlights in the treatment of chronic lymphocytic leukemia from the 2013 meeting of the American Society of Hematology. Molica S Expert Rev Hematol; 2014 Apr; 7(2):187-90. PubMed ID: 24617332 [TBL] [Abstract][Full Text] [Related]
3. Highlights in acute myeloid leukemia from the 2012 meeting of the American Society of Hematology. Stone RM Expert Rev Hematol; 2013 Apr; 6(2):127-9. PubMed ID: 23547861 [TBL] [Abstract][Full Text] [Related]
5. Highlights from the 58th meeting of the American Society of Haematology, 1-6 December 2016, San Diego, USA. Mazzarella L Ecancermedicalscience; 2017; 11():725. PubMed ID: 28386295 [TBL] [Abstract][Full Text] [Related]
6. Cancer-killing CAR therapies gain speed. Weber M Cancer Discov; 2015 Jan; 5(1):7. PubMed ID: 25583785 [TBL] [Abstract][Full Text] [Related]
8. Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation. Cieri N; Mastaglio S; Oliveira G; Casucci M; Bondanza A; Bonini C Immunol Rev; 2014 Jan; 257(1):165-80. PubMed ID: 24329796 [TBL] [Abstract][Full Text] [Related]
9. Of chimeric antigen receptors and antibodies: OX40 and 41BB costimulation sharpen up T cell-based immunotherapy of cancer. Hombach AA; Abken H Immunotherapy; 2013 Jul; 5(7):677-81. PubMed ID: 23829616 [No Abstract] [Full Text] [Related]
10. Advances in off-the-shelf CAR T-cell therapy. Benjamin R Clin Adv Hematol Oncol; 2019 Mar; 17(3):155-157. PubMed ID: 30969953 [No Abstract] [Full Text] [Related]
11. Next Steps in the CAR Journey of a Thousand Miles. Brenner MK Mol Ther; 2017 Oct; 25(10):2226-2227. PubMed ID: 28939089 [No Abstract] [Full Text] [Related]
13. Armed T cells with CAR for cancer immunotherapy. Wei YQ Sci China Life Sci; 2016 Apr; 59(4):331-2. PubMed ID: 27080712 [No Abstract] [Full Text] [Related]
14. Helping CAR T cells reach tumors. Cancer Discov; 2015 Jan; 5(1):OF6. PubMed ID: 25583818 [TBL] [Abstract][Full Text] [Related]
15. Highlights in Graft-vs-Host Disease From the 60th American Society of Hematology Annual Meeting: Commentary. Jagasia M Clin Adv Hematol Oncol; 2019 Mar; 17 Suppl 6(3):16-18. PubMed ID: 31730585 [No Abstract] [Full Text] [Related]
16. Fine-tuning the effects of T-cell therapy. Cancer Discov; 2014 Feb; 4(2):137. PubMed ID: 24501286 [TBL] [Abstract][Full Text] [Related]
17. Chimeric Antigen Receptor T Cells: Extending Translation from Liquid to Solid Tumors. Morgan MA; Schambach A Hum Gene Ther; 2018 Oct; 29(10):1083-1097. PubMed ID: 30156435 [TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen receptor T cell therapy: 25years in the making. Gill S; Maus MV; Porter DL Blood Rev; 2016 May; 30(3):157-67. PubMed ID: 26574053 [TBL] [Abstract][Full Text] [Related]
19. Chimeric T cells for adoptive immunotherapy of cancer: using what have we learned to plan for the future. Peinert S; Kershaw MH; Prince HM Immunotherapy; 2009 Nov; 1(6):905-12. PubMed ID: 20635906 [No Abstract] [Full Text] [Related]
20. American Association for Cancer Research: potential target antigens for cancer immunotherapy. April 1-5, 2000, San Francisco, CA, USA. Shankar G Expert Opin Investig Drugs; 2000 Jun; 9(6):1419-24. PubMed ID: 11203451 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]